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Background: Endothelial dysfunction caused by increased oxidative stress is a crit-
ical initiator of macro- and micro-vascular disease development in diabetic patients. 
Ipragliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, offers a novel 
approach for the treatment of diabetes by enhancing urinary glucose excretion. The aim 
of this study was to examine whether ipragliflozin attenuates endothelial dysfunction in 
diabetic mice.
Methods: Eight-week-old male C57BL/6 mice were treated with streptozotocin (150 mg/
kg) by a single intraperitoneal injection to induce diabetes mellitus. At 3 days of injection, 
ipragliflozin (3 mg/kg/day) was administered via gavage for 3 weeks. Vascular function 
was assessed by isometric tension recording. Human umbilical vein endothelial cells 
(HUVEC) were used for in vitro experiments. RNA and protein expression were examined 
by quantitative RT-PCR (qPCR) and western blot, respectively. Oxidative stress was 
determined by measuring urine 8-hydroxy-2′-deoxyguanosine (8-OHdG) level.
results: Ipragliflozin administration significantly reduced blood glucose level (P < 0.001) 
and attenuated the impairment of endothelial function in diabetic mice, as determined 
by acetylcholine-dependent vasodilation (P <  0.001). Ipragliflozin did not alter meta-
bolic parameters, such as body weight and food intake. Ipragliflozin administration 
ameliorated impaired phosphorylation of Akt and eNOSSer1177 in the abdominal aorta 
and reduced reactive oxygen species generation as determined by urinary excretion of 
8-OHdG in diabetic mice. Furthermore, qPCR analyses demonstrated that ipragliflozin 
decreased the expression of inflammatory molecules [e.g., monocyte chemoattractant 
Abbreviations: 8-OHdG, 8-hydroxy-2′-deoxyguanosine; Ach, acetylcholine; CMC, carboxymethyl cellulose; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; HDL, high-density lipoprotein; HUVEC, human umbilical vein endothelial 
cells; ICAM-1, intercellular adhesion molecule-1; MCP-1, monocyte chemoattractant protein-1; MGO, methylglyoxal; qPCR, 
quantitative RT-PCR; RAGE, receptor for AGE; ROS, reactive oxygen species; SGLT2, sodium-glucose cotransporter 2; SNP, 
sodium nitroprusside; STZ, streptozotocin; VCAM-1, vascular cell adhesion molecule-1.
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inTrODUcTiOn
Diabetes is a chronic metabolic disorder characterized by inap-
propriate hyperglycemia due to lack of or resistance to insulin. 
Reactive oxygen species (ROS) generated under a hyperglycemic 
state play a causal role in the vascular dysfunction observed in 
diabetic patients. A hyperglycemic state enhances the production 
of ROS through various pathways. ROS generation suppresses 
Akt-mediated eNOSSer1177 phosphorylation, leading to impair-
ment of endothelium-dependent NO-mediated vasorelaxation 
(1–7). Also, ROS induce activation of redox-sensitive transcrip-
tional factors, including NF-κB, and subsequently promote the 
expression of inflammatory molecules, such as intercellular adhe-
sion molecule (ICAM)-1 and vascular cell adhesion molecule 
(VCAM)-1, which stimulate endothelium–leukocyte interactions 
and accelerate the development of vascular inflammation (8–10). 
Furthermore, recent studies have also suggested that production 
of ROS is involved in the progression of diabetes directly (11). 
Therefore, when we consider treatment strategies for diabetes, the 
regulation of oxidative stress should be taken into account.
A new class of anti-diabetic drugs targets sodium-glucose 
cotransporter 2 (SGLT2), the main glucose transporter in the 
kidney, which is located in the S1 and S2 segments of the proximal 
tubule and is responsible for reabsorption of >90% of glucose 
in primary urine (12). In recent years, SGLT2 inhibitors, which 
can inhibit reabsorption of filtered glucose by blocking SGLT2, 
have been developed and proposed as novel hypoglycemic agents 
for treating patients with diabetes mellitus (13). In addition, in 
contrast to classical anti-diabetic therapies, SGLT2 inhibitors 
remove glucose from the body and are thereby expected to be 
highly efficient in preventing oxidative stress-associated organ 
damage. Ipragliflozin is a novel inhibitor of SGLT2, which is 
used for the treatment of type 2 diabetes (14–16). However, few 
studies have examined the vasoprotective effects of ipragliflozin. 
The purpose of this study was to investigate the hypothesis that 
inhibition of SGLT2 by ipragliflozin ameliorates endothelial 
dysfunction and vascular inflammation by inhibiting oxidative 
stress in STZ-induced diabetic mice.
MaTerials anD MeThODs
animals and Drug administration
Wild-type (C57BL/6J background) mice were purchased from 
Japan SLC, Inc. All experimental procedures conformed to the 
guidelines for animal experimentation of Tokushima University. 
To examine the effect of ipragliflozin on a diabetic mouse model, 
8-week-old male wild-type mice were treated with 150  mg/kg 
streptozotocin (STZ) or vehicle (citrate buffer) via intraperitoneal 
injection one time. Adverse effects of STZ injection (e.g., weight 
loss, respiratory distress, and poor body condition) were reported 
(17). In this experiment, two mice found dead within 1 week after 
STZ injection. One mouse was excluded due to weight loss by 
more than 20% from the baseline (18). From 3 days after injec-
tion, 3 mg/kg/day ipragliflozin was administered via oral gavage 
for 3 weeks. Ipragliflozin was suspended in 0.5% carboxymethyl 
cellulose (CMC) solution. STZ was purchased from Sigma-
Aldrich. Ipragliflozin was provided by Astellas Pharma, Inc. 
(Tokyo, Japan). The control group received an equal volume of 
CMC. Mice were maintained under a 12-h light/dark cycle with 
free access to normal chow and water.
laboratory Data
At the time of sacrifice, blood was collected from the heart into 
EDTA-containing tubes, and plasma was stored at −80°C until 
required. Plasma total cholesterol, high-density lipoprotein 
(HDL) cholesterol, and triglyceride levels were measured at 
LSI Medience Corporation (Japan). Urinary 8-hydroxy-2′-
deoxyguanosine (8-OHdG) concentration in a 16-h urine collec-
tion was determined using a commercially available kit (Japan 
Institute for the Control of Aging, Nikken SEIL Co., Ltd.) and 
corrected by creatinine.
Vascular reactivity assay
Analysis of vascular reactivity was performed, as described 
previously (19, 20). In brief, the descending thoracic aortas from 
mice were cut into 2-mm rings with special care to preserve the 
endothelium and mounted in organ baths filled with modified 
Krebs–Henseleit buffer (KHB; 118.4  mM NaCl, 4.7  mM KCl, 
2.5  mM CaCl2, 1.2  mM KH2PO4, 1.2  mM MgSO4, 25  mM 
NaHCO3, and 11.1  mM glucose) aerated with 95% O2 and 5% 
CO2 at 37°C. The preparations were attached to a force transducer, 
and isometric tension was recorded on a polygraph. Vessel rings 
were primed with 31.4 mM KCl, and then pre-contracted with 
phenylephrine, producing submaximal (60% of maximum) con-
traction. After the plateau was attained, the rings were exposed to 
increasing concentrations of acetylcholine (Ach, 10−9 to 10−4M) 
and sodium nitroprusside (SNP; 10−9 to 10−4M) to obtain cumula-
tive concentration–response curves.
protein-1 (MCP-1) vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhe-
sion molecule (ICAM)-1] in the abdominal aorta (P < 0.05). In in vitro studies, incubation 
with methylglyoxal, one of the advanced glycation end products, significantly impaired 
phosphorylation of Akt and eNOSSer1177 (P < 0.01) and increased the expression of MCP-
1, VCAM-1, and ICAM-1 in HUVEC.
conclusion: Ipragliflozin improved hyperglycemia and prevented the development of 
endothelial dysfunction under a hyperglycemic state, at least partially by attenuation of 
oxidative stress.
Keywords: sglT2 inhibitor, hyperglycemia, endothelial function, inflammation, oxidative stress
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cell culture
Human umbilical vein endothelial cells (HUVEC) were pur-
chased from Life Technologies and cultured in EGM-2 (Lonza). 
HUVEC (passage 4–6) were treated with methylglyoxal (MGO) 
(Sigma-Aldrich) in EBM-2 (Lonza) containing 2% FBS.
Western Blot analysis
Cell lysates were prepared using RIPA buffer (Wako Pure Chemical 
Industries, Ltd.) containing a protease inhibitor cocktail (Takara 
Bio Inc.) and phosphatase inhibitors (Roche). Proteins were 
separated by SDS-PAGE and transferred onto polyvinylidene dif-
luoride membranes (Hybond-P; GE Healthcare). After blocking 
with 5% bovine serum albumin, the membranes were incubated 
with primary antibody against either phosphorylated-eNOSSer1177, 
Akt, phosphorylated-AktSer473 (Cell Signaling Technology), 
eNOS (BD Biosciences), or β-actin (Sigma) overnight at 
4°C. Horseradish peroxidase-conjugated anti-mouse Ig (Cell 
Signaling Technology) or anti-rabbit Ig (Chemicon) antibody 
was then used as the secondary antibody. Antibody distribution 
was visualized with ECL-plus reagent (GE Healthcare) using a 
luminescent image analyzer (LAS-1000, Fuji Film).
real-time Polymerase chain reaction
Total RNA was extracted from the aorta and cells using an 
illustra RNAspin RNA Isolation Kit (GE Healthcare). cDNA 
was synthesized from 100 ng of total RNA using a QuantiTect 
Reverse Transcription kit (Qiagen). Quantitative RT-PCR 
(qPCR) was performed on an Mx3000P (Agilent Technologies) 
using Power SYBR Green PCR Master Mix (Applied Biosystems). 
Mouse PCR primers were as follows: VCAM-1, sense 5′-CCCG 
TCATTGAGGATATTGG-3′ and antisense 5′-GGTCATTGTC 
ACAGCACCAC-3′; ICAM-1, sense 5′-TTCACACTGAATGC 
CAGCTC-3′ and antisense 5′-GTCTGCTGAGACCCCTCT 
TG-3′; monocyte chemoattractant protein (MCP)-1, sense 5′-CC 
ACTCACCTGCTGCTACTCAT-3′ and antisense 5′-TGGTGAT 
CCTCTTGTAGCTCTCC-3′; F4/80, sense 5′-TGCATCTAGCA 
ATGGACAGC-3′ and antisense 5′-GCCTTCTGGATCCATTT 
GAA-3′; and β-actin, sense 5′-CCTGAGCGCAAGTACTCT 
GTGT-3′ and antisense 5′-GCTGATCCACATCTGCTGGAA-3′. 
Human PCR primers were as follows: VCAM-1, sense 5′-ATGA 
ATTCGAACCCAAACA-3′ and antisense 5′-CCTGGCTCAAG 
CATTGTCATA-3′; MCP-1, sense 5′-CCCCAGTCAACCGCTG 
TTAT-3′ and antisense 5′-AGATCTCCTTGGCCACAATG-3′; 
ICAM-1, sense 5′-TGATGGGCAGTCAACAGCTA-3′ and 
antisense 5′-GGGTAAGGTTCTTGCCCACT-3′; and glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH), sense 5′-TGG 
GTGTGAACCATGAGAAG-3′ and antisense 5′-GCTAAGCA 
GTTGGTGGTGC-3′. Data are expressed in arbitrary units that 
were normalized by β-actin or GAPDH.
statistical analysis
All results are expressed as mean ± SEM. Comparison of param-
eters between two groups was performed with unpaired Student’s 
t-test. Differences between multiple groups were analyzed by one-
way analysis of variance (ANOVA), followed by Tukey’s post hoc 
analysis. Comparisons of dose–response curves were made by 
two-factor repeated-measures ANOVA, followed by Tukey’s 
post hoc test for comparison between groups. A value of P < 0.05 
was considered significant.
resUlTs
ipragliflozin Decreased Blood glucose 
level in sTZ-induced Diabetic Mice
In this study, STZ injection markedly elevated the non-
fasting blood glucose level compared with that in control mice. 
Ipragliflozin significantly decreased the non-fasting blood glu-
cose level compared with the vehicle-treated group (Figure 1A). 
There were no significant differences in the plasma levels of 
total cholesterol, HDL cholesterol, and triglyceride between the 
ipragliflozin-treated and vehicle-treated groups in STZ-induced 
diabetic mice (Table 1). STZ injection significantly reduced body 
weight and increased food and water intake, although there 
was no difference between the ipragliflozin-treated and vehicle-
treated groups, as shown in Table 1 and Figure 1B. Ipragliflozin 
increased urine volume (vehicle vs. ipragliflozin; 9.5 ±  1.1 vs. 
11.2 ±  2.0  ml/day) and urinary glucose excretion (vehicle vs. 
ipragliflozin; 617.7 ± 60.5 vs. 802.7 ± 133.5 mg/day) in diabetic 
mice, although they did not reach statistical significance.
ipragliflozin ameliorated endothelial 
Dysfunction in sTZ-induced Diabetic Mice
In diabetes, vascular dysfunction is characterized by impaired 
endothelial function due to increased oxidative stress. Therefore, 
to investigate the effects of ipragliflozin on endothelial function, 
vascular response was examined. Endothelium-dependent vaso-
dilation in response to Ach was impaired in STZ-induced diabetic 
mice compared with that in the control group (P < 0.001); how-
ever, ipragliflozin administration significantly ameliorated the 
impairment of endothelium-dependent vasodilation (P < 0.001) 
(Figure 2A). On the other hand, endothelium-independent relax-
ation in response to SNP did not differ between the ipragliflozin-
treated group and vehicle-treated group (Figure 2B). Compared 
with non-diabetic control, STZ injection increased urinary excre-
tion of 8-OHdG (P < 0.05), which was significantly ameliorated 
by ipragliflozin administration (P < 0.05) (Figure 2C).
effects of ipragliflozin on endothelial 
Function in sTZ-induced Diabetic Mice
To investigate the mechanism by which ipragliflozin improved 
endothelial function, we examined phosphorylation of eNOS and 
Akt. Phosphorylation of eNOS at Ser1177, which increases eNOS 
activity, was impaired in STZ-induced diabetic mice; however, 
ipragliflozin ameliorated this impairment (P < 0.05) (Figure 3A). 
STZ-induced diabetic mice also showed reduction of Akt phos-
phorylation, and this downregulation of Akt phosphorylation 
was restored by ipragliflozin treatment (P < 0.01) (Figure 3B).
We also examined the effects of ipragliflozin on the expression 
of inflammatory molecules in the abdominal aorta using qPCR. 
Ipragliflozin treatment decreased the expression of ICAM-1, 
VCAM-1, and MCP-1 (P < 0.05) in the abdominal aorta com-
pared with vehicle treatment in STZ-induced diabetic mice 
(Figure 3C), suggesting inhibition of inflammatory activation of 
TaBle 1 | effects of ipragliflozin treatment on metabolic parameters.
ctrl (N = 11) sTZ (N = 13) sTZ + ipra (N = 14)
Blood glucose, mg/dl 138.0 ± 3.8 600.6 ± 45.0††† 431.8 ± 33.6***†††
Body weight, g 25.3 ± 0.4 20.4 ± 0.7††† 20.2 ± 0.6†††
Total cholesterol, mg/dl 86.0 ± 5.9 113.8 ± 12.0 130.1 ± 13.0†
Triglyceride, mg/dl 66.5 ± 9.8 137.9 ± 32.6 157.3 ± 37.0†
HDL-cholesterol, mg/dl 49.5 ± 3.5 62.0 ± 6.4 71.0 ± 6.3
Ctrl; control, STZ; streptozotocin, Ipra; ipragliflozin; HDL; high-density lipoprotein.
All values are mean ± SEM.
†P < 0.05 and †††P < 0.001 vs. control and ***P < 0.001 vs. STZ.
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FigUre 1 | effect of ipragliflozin administration on non-fasting blood glucose level. (a) Ipragliflozin administration to STZ-induced diabetic mice significantly 
decreased non-fasting blood glucose level compared with vehicle. (B) STZ injection significantly increased food and water intake, although there was no difference 
between the ipragliflozin-treated and vehicle-treated groups. Ctrl, control (non-STZ injected); Ipra, ipragliflozin. *P < 0.05 and ***P < 0.001 vs. STZ group. ††P < 0.01 
and †††P < 0.001 vs. Ctrl group. Data represent mean ± SEM.
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endothelial cells by ipragliflozin in a diabetic condition. In fact, 
the expression of F4/80, a macrophage marker, in the aorta was 
reduced in ipragliflozin-treated diabetic mice (Figure 3C).
effects of glucose Toxicity on endothelial 
cell Function
Hyperglycemia promotes oxidative stress by contributing to the 
production of advanced glycation end products (AGEs), leading 
to an increase in intracellular oxidants, a decrease in bioavail-
ability of endothelium-derived NO, and the development of 
vascular inflammation. Therefore, to investigate the effects of 
AGE on endothelial cell function, in vitro studies using HUVEC 
were performed. Incubation with MGO, a major precursor of 
AGEs, significantly reduced the phosphorylation of eNOS at 
Ser1177 and Akt (P < 0.01) (Figures 4A,B). MGO also increased 
the expression of ICAM-1, VCAM-1, and MCP-1 in HUVEC 
(Figure 4C). These results correspond to the results we observed 
in in vivo studies, suggesting that ipragliflozin treatment attenu-
ated endothelial dysfunction by reducing glucose toxicity.
DiscUssiOn
SGLT2 inhibitors excrete excess glucose into the urine and exhibit 
an anti-hyperglycemic effect (18, 21, 22). Hyperglycemia has been 
recognized as a primary factor in endothelial dysfunction, lead-
ing to the development of diabetic micro- and macro-vascular 
complications in diabetic patients. In this study, we demonstrated 
that administration of ipragliflozin, a SGLT2 inhibitor, to STZ-
induced diabetic mice lowered the blood glucose level and pre-
vented the development of endothelial dysfunction and vascular 
inflammation, at least partially through a reduction of oxidative 
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FigUre 2 | ipragliflozin attenuated endothelial dysfunction in sTZ-induced diabetic mice. (a,B) Vascular reactivity to Ach or SNP was determined using 
aortic rings isolated from ipragliflozin- or vehicle-administered STZ-induced diabetic mice and control mice. Ipragliflozin administration for 3 weeks ameliorated 
endothelium-dependent vasodilation in response to Ach compared with the non-treated diabetic group (a). Vasorelaxation in response to SNP did not differ among 
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stress. Accumulating evidence suggests cardioprotective effects 
of SGLT2 inhibitors (23, 24). Our study might provide one of the 
mechanisms for these effects.
Previous studies have revealed that the cardiovascular 
consequences of diabetes mellitus are associated with oxidative 
stress (25–27). A hyperglycemic state increased non-enzymatic 
glycosylation of proteins and subsequent formation of AGE, 
which interact with the receptor for AGE (RAGE) on the plasma 
membrane and promote the production of ROS, contributing 
to vascular complications (28). Also, hyperglycemic state can 
activate polyol pathways and PKC, promoting ROS generation 
(29, 30). Previous basic and clinical studies have shown that 
ROS generation suppresses Akt-mediated eNOSSer1177 phospho-
rylation, leading to the impairment of endothelium-dependent 
NO-mediated vasorelaxation (1–7). In this study, ipragliflozin 
improved endothelium-dependent vasodilation in STZ-induced 
diabetic mice, indicating its protective effects on endothelial cell 
function in a hyperglycemic state. Our results demonstrated that 
ipragliflozin increased the phosphorylation of eNOS at Ser1177 
and Akt in the aorta of diabetic mice. Therefore, the improvement 
of vascular endothelial function by ipragliflozin in diabetic mice 
seems to be at least partially attributable to the improvement of 
eNOS function in a hyperglycemic state. The results of in vitro 
experiments demonstrating attenuation of Akt and eNOS phos-
phorylation in HUVEC treated with MGO, the precursor of AGE, 
support our in vivo results. These results suggest that a reduction 
of oxidative stress through the excretion of excess glucose is 
one of the mechanisms of the cardioprotective effects of SGLT2 
inhibitors. In addition, our present study demonstrated that the 
glucose-lowering effect of ipragliflozin in STZ-induced diabetic 
mice significantly decreased oxidative stress as determined by 
urinary excretion of 8-OHdG. Previous studies have also shown 
that treatment with empagliflozin, another SGLT2 inhibitor, for 
7 or 10  weeks improved endothelial function in STZ-induced 
and obesity-induced diabetic animal models (22, 31), whereas, in 
this study, we observed improvement of endothelial function in 
an even shorter treatment period, suggesting the reliability and 
effectiveness of glucose-lowering therapy with SGLT2 inhibitors 
for improving endothelial function.
A hyperglycemic state also induces proinflammatory activa-
tion of endothelial cells. Several studies performed in diabetic 
patients, animals, and high-glucose-treated endothelial cells dem-
onstrated that hyperglycemia-induced ROS formation in various 
cells (32–35) induces the activation of NF-κB and subsequent 
inflammation (8–10). Our present study showed that hypergly-
cemia induced by STZ increased the expression of inflammatory 
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molecules, such as ICAM-1 and VCAM-1, in the aorta, which 
was suppressed by ipragliflozin treatment. The results of in vitro 
experiments in which MGO increased the expression of these 
inflammatory molecules in HUVEC support our in vivo results. 
These results also suggest cardioprotective effects of ipragliflozin.
This study was performed in a STZ-induced diabetic model, a 
model of type 1 diabetes. It is unclear whether the present results 
from a type 1 diabetes model are translatable to type 2 diabetes, 
which is the most common type of diabetes in humans. This is a 
major limitation for translating our findings to the clinical situ-
ation. However, several studies have already demonstrated that 
other SGLT2 inhibitors prevented vascular dysfunction in type 2 
diabetes (13, 15, 21, 31). Also, several studies reported the poten-
tial of SGLT2 inhibitors, such as dapagliflozin, in type 1 diabetes 
(36). Therefore, the results of this study support the concept that 
the glucose-lowering effect of SGLT2 inhibitors is associated with 
cardioprotective effects of this class of anti-diabetic drug. In this 
experiment, urine volume and urinary glucose excretion between 
vehicle-treated and ipragliflozin-treated diabetic mice did not 
differ significantly. SGLT2 inhibitors increase urinary glucose 
excretion and consequently increase urine volume. However, sev-
eral studies reported that long-term treatment did not increase 
urinary glucose excretion and urine volume significantly due to 
the reduction of blood glucose level (31, 37). The results of our 
present study corresponded with those studies.
In conclusion, our results demonstrated that ipragliflozin 
improved endothelial dysfunction in STZ-induced diabetic 
mice. The beneficial effect of ipragliflozin was associated, at 
p-eNOS
t-eNOS
MGO, μM 100 5000
100 500
0
0.2
0.4
0.6
0.8
1.0
1.2
p-
eN
O
S/
t-e
N
O
S
**
0MGO, μM
0
0.2
0.4
0.6
0.8
1.0
1.2
100
p-
A
kt
/t-
A
kt
500
**
0MGO, μM
p-Akt
t-Akt
MGO, μM 100 5000
0
0.5
1.0
1.5
2.0
MGO, μM 5000
V
C
A
M
-1
/β
-a
ct
in
0
0.5
1.0
1.5
MGO, μM 5000
M
C
P-
1/
β-
ac
tin
**
0
0.5
1.0
1.5
MGO, μM 5000
IC
A
M
-1
/β
-a
ct
in
*
A
B
C
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demonstrated that incubation of HUVEC with 500 μM MGO for 4 h significantly increased the expression of ICAM-1 and MCP-1 and tended to increase VCAM-1 
(P = 0.06). n = 4 per group. Ctrl, control; MGO, methylglyoxal. *P < 0.05 and **P < 0.01 vs. Ctrl. All values are mean ± SEM.
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least in part, with a reduction of oxidative stress. Taken together 
with the results of previous studies, our results reveal one of 
the mechanisms of the cardioprotective effects of SGLT2 inhibi-
tors. Further studies are needed to elucidate these mechanisms, 
although our present study supports the results of recent clinical 
studies that suggested cardioprotective effects of SGLT2 inhibi-
tors (23, 24).
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